Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Zydus Lifesciences Ltd

| Q2 FY26 Post Results Earnings Call

NEUTRAL SENTIMENT

Report Source

⬤6th Nov 25

Summary : Zydus Lifesciences reported strong Q2 FY26 growth, driven by US formulations, India branded business, and strategic acquisitions in consumer wellness and MedTech, while advancing its specialty pipeline and maintaining profitability targets.

Management Perspective positive : Management expressed pleasure with robust financial performance and confidence in future growth across segments. They highlighted strategic acquisitions and pipeline developments as key drivers, maintaining a positive outlook despite some challenges.

Concall Report Analysis & Insights

Business Overview

  1. Consolidated revenues grew 17% year-on-year to Rs. 61.2 billion in Q2 FY26.
  2. EBITDA increased 38% year-on-year to Rs. 20.2 billion, with a 32.9% margin.
  3. US formulations business achieved strong double-digit growth from volume and new products.
  4. India's branded formulations business outpaced market growth, especially in chronic segments.
  5. Acquired UK-based Comfort Click Limited, entering the high-growth VMS segment.
  6. Completed 100% acquisition of Amplitude Surgical, expanding MedTech presence.

Future Growth Prospects

  1. Saroglitazar Magnesium NDA filing with USFDA expected in Q4 FY26 for PBC indication.
  2. Expanding MedTech focus in orthopedics, nephrology, and cardiology globally.
  3. Launching new products like Beizray (docetaxel injection) and generic Copaxone soon.
  4. Initiating Phase II clinical trials for Bivalent Typhoid Conjugate vaccine in India.
  5. Targeting global tenders for vaccines, including TCV and flu, for international expansion.

Management Insights

  1. Pleased with robust financial performance and healthy growth across key segments.
  2. Committed to accelerating innovation for long-term growth and meeting diverse patient needs.
  3. US business is well-positioned for sustained growth through diversified portfolio and specialty focus.
  4. Building on India's branded formulations momentum with innovation and broader customer reach.
  5. Comfort Click acquisition enhances global digital health footprint and personalized wellness.

Signs of Skepticism

  1. Uncertainty regarding the exact impact of Revlimid's sales decline on FY27 US revenues.
  2. The significant increase in other operating expenses due to M&A activities requires close monitoring.
  3. Long-term scaling of new ventures like MedTech and vaccines still requires significant time and investment.
  4. Details on Saroglitazar's comparative advantages and full trial results are pending publication.

Risk Factors

  1. Revlimid sales are significantly lower in Q2 and expected to decline further.
  2. US revenues for FY27 are uncertain without Revlimid, pending court decisions.
  3. MedTech business in Europe faces price regulations and negotiations every 3-4 years.
  4. Increased operating expenses due to recent acquisitions of Amplitude and CCL.

Good To Know

  1. Oncology injectable and Baddi formulations facilities received EIR reports with voluntary action from USFDA.
  2. Chronic portfolio contribution increased to 44.5% as per IQA MAT September '25.
  3. Launched VaxiFlu, India's first trivalent influenza vaccine, aligning with WHO recommendations.
  4. Acquisition of Comfort Click marks entry into the £11 billion European VMS market.
  5. Fundraising initiative aims to deleverage the balance sheet and enable future strategic acquisitions.

Key Drivers

  1. Saroglitazar US filing for PBC.
  2. New product launches in US.
  3. MedTech expansion globally.
  4. Vaccine tenders, international market.

Key Analyst Discussions

Competitive Environment

  1. Saroglitazar for PBC will be potentially the third drug on the market, seeing good traction for this class.
  2. MedTech business faces price negotiations every 3-4 years, similar to generics.
  3. Dialyzer membrane market in India currently has no local manufacturers, offering a first-mover advantage.
  4. US base business experiences single-digit price erosion, which is maintained.

Market Trends & Consumer Behavior

  1. VMS market in Europe is high-growth, driven by rising health awareness and preventive healthcare focus.
  2. Myrbetriq is showing good traction and steady market share increase.
  3. Influenza remains a significant global health concern, driving vaccine demand.

Financial Highlights

  1. Other operating expenses increased 32% due to Amplitude and CCL acquisitions.
  2. Run-rate for operating expenses post-acquisition is expected to be Rs. 1,500-1,550 crores.
  3. Net debt to EBITDA ratio target is below one time, with a temporary allowance up to two times for acquisitions.
  4. Company maintains 26% plus operating margin guidance for the full year despite lower Comfort Click margins.

Product Composition

  1. Revlimid sales significantly decreased in Q2 and are expected to be minimal in Q3.
  2. Saroglitazar met its primary endpoint in PBC trial; full results to be published in May ESL.
  3. CUTX-101 is expected to launch between January and June 2026.
  4. Injectables business, including 505(b)(2) products like Beizray, is expected to scale up in 2-3 years.
  5. Vaccine portfolio includes flu, rabies, and TCV, with significant market share in India.

Strategic Considerations

  1. Fundraising aims to deleverage debt and provide flexibility for US specialty and international market acquisitions.
  2. MedTech expansion will leverage Amplitude's portfolio and build new facilities for nephrology.
  3. Company prioritizes building its own commercial capability for Saroglitazar but is open to partnerships.
  4. Leadership teams of acquired entities (Amplitude, Comfort Click) are incentivized with long-term plans.
Zydus Lifesciences Ltd (ZYDUSLIFE) Concall Report Analysis & Insights | Dhanarthi